PROTOCOL 30012 Randomized phase III Trial Interleukin-2 协议30012随机III期试验，白细胞介素-2.pptVIP

下载本文档

10
0
约8.25千字
约 27页
2018-04-17 发布于江西
举报
版权申诉

PROTOCOL 30012 Randomized phase III Trial Interleukin-2 协议30012随机III期试验，白细胞介素-2.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

PROTOCOL 30012 Randomized phase III Trial Interleukin-2 协议30012随机III期试验，白细胞介素-2.ppt

EORTC STBSG Ongoing clinical trials Venice, November 4th PROTOCOL 62981: Randomized Phase III study to evaluate the role of high dose chemotherapy intensification in the treatment of intermediate prognosis Ewing’s sarcoma and Primitive Neuroectodermal Tumour (PNET) PROTOCOL 62991-22998: Phase II study of moderate dose radiotherapy for inoperable aggressive fibromatosis PROTOCOL 62991-22998: ACCRUAL GRAPH PROTOCOL 62012: Randomized trial of single agent doxorubicin versus doxorubicin plus ifosfamide PROTOCOL 62022: Phase II study of Iressa (ZD1839) in locally advanced and/or metastatic synovial sarcoma PROTOCOL 62024: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery PROTOCOL 62024: Accrual by Group PROTOCOL 62024: Stratification factors PROTOCOL 62027: Phase II study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcoma expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF-beta fusion protein i.e DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF). 62027 Accrual Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma EORTC study 62043 Accrual graph (cut-off 11 Oct ’06) Phase II study of E7389 administered as an IV infusion day 1 and 8 every 3 weeks in pretreated patients with advanced and/or metastatic soft tissue sarcoma EORTC study 62052 Trial 62052 Study Coordinator : Dr. Patrick Schoeffski (Leuven, Belgium) Date of PRC protocol approval: July 17, 2006 Version and date of last amendment: first amendment (non-substantial) protocol version 1.1, August 8, 2006 Treatment scheme : Intravenous bolus of E7389 (1.4 mg/m2) on days 1 and 8 every 21 days Sample size Randomized Phase II study of brostacillin (PNU-166196A) versus doxorubicin as first line chemotherapy in